Armistice Capital’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Armistice Capital’s Portfolio NLSPW Stock Details NLSPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,500	Closed	-$250	–	370
2025 Q2	$250	Hold	12,500	–	–	﹤0.01%	205
2025 Q1	$161	Hold	12,500	–	–	﹤0.01%	225
2024 Q4	$163	Hold	12,500	–	–	﹤0.01%	224
2024 Q3	$143	Sell	12,500 -487,500	-98%	-$14.3K	﹤0.01%	258
2024 Q2	$17.3K	Hold	500,000	–	–	﹤0.01%	241
2024 Q1	$24.5K	Hold	500,000	–	–	﹤0.01%	318
2023 Q4	$28.1K	Hold	500,000	–	–	﹤0.01%	268
2023 Q3	$52.6K	Hold	500,000	–	–	﹤0.01%	227
2023 Q2	$53.5K	Sell	500,000 -1	-0%	–	﹤0.01%	201
2023 Q1	$75K	Buy	500,001 +1	+0%	–	﹤0.01%	198
2022 Q4	$145K	Hold	500,000	–	–	﹤0.01%	158
2022 Q3	$125K	Hold	500,000	–	–	﹤0.01%	174
2022 Q2	$60	Hold	500,000	–	–	﹤0.01%	172
2022 Q1	$190K	Hold	500,000	–	–	﹤0.01%	128
2021 Q4	$250K	Hold	500,000	–	–	﹤0.01%	142
2021 Q3	$413K	Hold	500,000	–	–	0.01%	131
2021 Q2	$452K	Hold	500,000	–	–	0.01%	114
2021 Q1	$475K	Buy	+500,000	New	+$455K	0.01%	106

Other funds holding NLSPW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Armistice Capital's NLSPW Position: Q3 2025 in Review

Armistice Capital sold out of NLS Pharmaceutics Warrant (NLSPW) in Q3 2025, closing a stake of 12,500 shares — an estimated $250 sold.

Armistice Capital first reported a position in NLSPW in Q1 2021 and held it in 18 quarters. The position peaked at $475K in Q1 2021. 3 funds tracked by Wall St. Rank hold NLSPW as of Q3 2025.

Armistice Capital reported no remaining NLS Pharmaceutics Warrant position as of Q3 2025 after selling out during the quarter.
Armistice Capital sold 12,500 NLS Pharmaceutics Warrant shares in Q3 2025, an estimated $250.
Armistice Capital first reported a position in NLS Pharmaceutics Warrant in Q1 2021 and held it in 18 quarters.
Armistice Capital's NLS Pharmaceutics Warrant position peaked at $475K in Q1 2021.
3 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.